Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.
Rashmi B Halker SinghErnesto AycardiMarcelo E BigalPippa S LoupeMirna McDonaldDavid W DodickPublished in: Cephalalgia : an international journal of headache (2018)
Post-hoc results must be interpreted with caution; nonetheless, a statistically significant percentage of patients who initially responded to fremanezumab within 1 month sustained this response over the subsequent 2 months. Sustained reduction in individual patients may provide a novel patient-centric, clinically meaningful endpoint for future trials assessing the effectiveness of preventive migraine treatments. Trials are registered as http://clinical trials.gov as NCT02025556 and NCT02021773.
Keyphrases
- end stage renal disease
- clinical trial
- chronic kidney disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- systematic review
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- case report
- intensive care unit
- respiratory failure
- extracorporeal membrane oxygenation
- open label
- phase ii
- patient reported